[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taiwan Bio Therapeutics Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100494930",false,"NCT05724576","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.","Inclusion Criteria:\n\n* Patents, with age ≤20 or ≤80 years old.\n* Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction):\n\n  1. Chest pain onset.\n  2. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.\n  3. TnT-I elevation.\n* Into emergency ≤ 6h upon AMI presentation.\n* Patients are willing to receive the treatment and sign the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\>80 years old.\n* History of\n\n  1. Malignancy.\n  2. Sepsis (abnormal WBC count elevation).\n  3. Hematologic disorder.\n  4. AIDS.\n  5. Advanced liver cirrhosis.\n  6. CKD stage 5 with Ccr \\\u003C15 ml\u002Fmin.\n* AMI occurrence \\> 6 hours\n* Non-first AMI.\n* Pregnancy or breastfeeding.\n* Prison.\n* Cancer treatment within 2 years.\n* Expected lifespan \\\u003C 6 months.\n* Non-suitable candidate evaluated by PI.\n* Participating in other clinical trials.","ALL","20 Years","80 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.",[26],"Safety Issues",[28,29,30],"MSC","AMI","PCI","RECRUITING","2025-06-04",{"date":34,"type":35},"2025-06-06","ACTUAL",{"date":37,"type":35},"2023-06-26",{"date":39,"type":20},"2026-03-01",{"name":41,"class":42},"Taiwan Bio Therapeutics Inc.","INDUSTRY",""]